Tonix Pharmaceuticals names CEO Seth Lederman as interim chief medical officer
The board added the interim CMO role to Lederman's existing duties as president, CEO, and chairman, effective August 18, 2026.
Tonix Pharmaceuticals Holding Corp. disclosed in an 8-K filing that its board of directors took action on August 18, 2026 regarding executive appointments. The board appointed Dr. Seth Lederman, the company's President and Chief Executive Officer, to also serve as Interim Chief Medical Officer.1
Lederman, 69, is not new to the company's leadership. He has held the roles of President, Chief Executive Officer, and Chairman of the Board since October 2011, and he will keep those positions alongside the new interim CMO title.1
The filing addressed potential conflicts tied to the appointment. The company stated that no arrangements or understandings exist between Lederman and any other party connected to his selection as Interim Chief Medical Officer.1 It also stated that there are no family relationships between Lederman and any other director or executive officer of the company.1
Separately, under Item 8.01 of the filing, Tonix confirmed the news publicly. The company announced the appointment of Dr. Lederman to Interim Chief Medical Officer on August 18, 2026.1
The 8-K was signed by Chief Financial Officer Bradley Saenger on behalf of the company on the same date. The filing did not specify a term length for the interim CMO role or name a permanent successor search timeline.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.